Here is the design of a clinical trial:

Official Title: A Randomized, Controlled, Multicenter, Open Label Phase II Clinical Study to Evaluate Infliximab in the Treatment of Patients With Severe COVID-19 Disease

Included conditions:
- COVID-19

Study Armgroups:
- {'label': 'Infliximab + Standard of Care', 'type': 'EXPERIMENTAL', 'interventionNames': ['Drug: Infliximab', 'Other: Standard of Care']}
- {'label': 'Standard of Care', 'type': 'ACTIVE_COMPARATOR', 'interventionNames': ['Other: Standard of Care']}

Interventions:
- {'type': 'DRUG', 'name': 'Infliximab', 'description': 'single intravenous administration of 5 milligrams/kilogram', 'armGroupLabels': ['Infliximab + Standard of Care']}
- {'type': 'OTHER', 'name': 'Standard of Care', 'description': 'Standard of Care', 'armGroupLabels': ['Infliximab + Standard of Care', 'Standard of Care']}

Primary Outcomes:
- {'measure': '28-day mortality', 'description': 'differences in mortality-rates between both study arms (Infliximab + Standard of Care vs. Standard of Care) 28 days after randomisation', 'timeFrame': '28 days after randomization'}

Please estimate the sample size based on the assumption: 
Two-sided Fisher’s exact test, significance level alpha = 0.05, power = 95%, dropout rate = 10%
Sample size and statistical analysis
        Sample size planning was based on unpublished retrospective data from Jena University Hospital (April 2020âJanuary 2021, part of the data set in [29]). In 31 patients, the 28-day mortality was 50% in SOC and 12.2% in patients with SOC + infliximab. Under these assumptions, a two-sided Fisherâs exact test at significance level alphaâ=â0.05 has a power of 95%, if 40 patients are included in each of the two groups. Allowing for a dropout rate of 10%, the total number of patients to be randomised is 88 (2 Ã 44). We used nQuery 7.0 (Statistical Solutions Ltd, Cork, Ireland) for sample size planning. The full analysis set population (FAS) includes all patients enrolled and randomised to the study with at least one observation after randomisation. Patients will be analysed as randomised (intention-to-treat principle). The primary efficacy analysis will be conducted in the FAS. All variables collected will be analysed in the FAS. The per-protocol collective includes all patients in the intention-to-treat collective who do not have major protocol deviations. In sensitivity analysis, the primary efficacy analysis will be repeated in the per-protocol collective. If there are differences between randomised and actual treatment, an additional âas treatedâ sensitivity analysis will be performed. An interim-analysis is not planned. Data analysts will be blinded.